OCTOBER 30, 2024

Expert Picks From EASL 2024

Data on denifanstat and tirzepatide for MASH, larsucosterol for alcohol-associated hepatitis, and more

In this installment of Expert Picks, from EASL 2024, Ashwani K. Singal, MD, MS, a professor of medicine at the University of Louisville School of Medicine, transplant hepatologist at Jewish Hospital at Trager Transplant Center, and research scientist at Rob Rexley VA Medical Center, in Louisville, highlights four abstracts from the meeting.


Abstract GS-011. Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in